An interventional study of Usual practice pattern (UPP) and Experimental: Enhanced Telehealth (ET) in Breast Cancer and Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Health services research
Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care. MSK's goal is to make getting cancer care easier by cutting down the need to make in-person visits to MSK. MSK is trying to do this through a new option called enhanced telehealth.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's planned enrollment of 1,750 is above the median of 72 across 9,302 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,930 studies on the registry; 328 are open to participants now.
Of its 129 completed or terminated interventional studies of FDA-regulated products, 66 (51%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Usual practice pattern (UPP) of patient's medical oncologist
Other: Usual practice pattern (UPP) · Other: Experimental: Enhanced Telehealth (ET)
Enhanced Telehealth (ET) practice pattern of patient's medical oncologist
Other: Usual practice pattern (UPP) · Other: Experimental: Enhanced Telehealth (ET)
Patient follows usual practice pattern for routine care
Patient follows enhanced telehealth practice pattern. As clinically appropriate, patients given option to shift routine care from face-to-face to at-home services available at institution: telehealth visits, home phlebotomy, and educational support for home administration of injection medications
Proportion of routine face to face medical oncology related visits out of total medical oncology related visits
all patients who meet eligibility criteria and have completed at least 2 medical oncology visits during the 12 month follow up period will be included for endpoint evaluability during analyses
Time frame: 12 months
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center